Immunocore Holdings (IMCR) Current Deferred Revenue (2019 - 2026)

Immunocore Holdings has disclosed Current Deferred Revenue across 6 years of filings, most recently posting $572000.0 for Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $572000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $572000.0 (changed N/A YoY), and the FY2025 annual result was $583000.0, changed N/A from the prior year.
• Current Deferred Revenue came in at $572000.0 for Q1 2026 at Immunocore Holdings, down from $583000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $7.5 million in Q4 2022 to a low of $572000.0 in Q1 2026.
• The 3-year median for Current Deferred Revenue is $583000.0 (2025), against an average of $2.0 million.
• Peak annual rise in Current Deferred Revenue reached 77.2% in 2022, while the deepest fall reached 77.2% in 2022.
• Immunocore Holdings' Current Deferred Revenue stood at $7.5 million in 2022, then tumbled by 92.24% to $583000.0 in 2025, then retreated by 1.89% to $572000.0 in 2026.
• The last three Current Deferred Revenue figures came in at $572000.0 (Q1 2026), $583000.0 (Q4 2025), and $582000.0 (Q3 2025), per Business Quant data.